370
Views
2
CrossRef citations to date
0
Altmetric
Editorial

Economic evaluation tailored to promote vaccine uptake: how third world consumers can respond

&
Pages 515-516 | Published online: 09 Jan 2014

References

  • Shaw GB. The Doctors Dilemma. Penguin Books, London, UK, 33 (1957) (First published 1911).
  • Walker DG, Rheingans R. The cost–effectiveness of rotavirus vaccines. Expert Rev. Pharmacoeconomics Outcomes Res. 5(5), 593–601 (2005).
  • Puliyel J. Dummies guide to risk-benefit analysis of vaccines. Pediatrics 110, 193 (2002).
  • Puliyel JM. Policy analysis of the use of hepatitis B, Hemophilus Influenza type B, Streptococcus pneumonia-conjugate vaccine and Rotavirus vaccine in the National Immunization Schedules. Health Econ.13, 1147 (2004).
  • Miller M. Authors reply: policy analysis of the use of hepatitis B, Hemophilus Influenza type B, Streptococcus pneumonia-conjugate vaccine and Rotavirus vaccine in the National Immunization Schedules. Health Econ. 13, 1147–1148 (2004).
  • Lieu WA, Coch SL, Black SA et al. Cost effectiveness of a varicella vaccination programme foe US children. JAMA 27, 375–381 (1994).
  • Levine OS, Schwartz B, Pierce N, Kne M, Development evaluation and implementation of Haemophilus influenza type b vaccie for young children in developing countries: current status and priority actions. Pediatr. Infect. Dis. J. 17, 95–113 (1998).
  • Levine O, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22–25, 2002. J. Pediatr. 143(6 Suppl.), S163–S187 (2003).
  • Invasive Bacterial InfectionsSurveillance (IBIS) Group of the International Clinical EpidemiologyNetwork. Are Haemophilus influenzae infections a significant problem in India? A prospective study and review. Clin. Infect. Dis. 34(7), 949–957 (2002).
  • Watt JP, Levine O, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22–25, 2002 J. Pediatr. 143(6 Suppl.), S163–S187 (2003).
  • Tyagi V, Singh SK, Sawhney A, Taneja V, Puliyel JM. Using gross national product to calculate acceptable immunization costs: deploying cost-effectiveness calculations in reverse. Pharmacoeconomics 21, 497–499 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.